Surat-based Anupam Rasayan India to acquire upto 74.2 per cent in Bliss GVS Pharma

Surat-based Anupam Rasayan India Ltd stated it was buying upto 74.2 per cent in Bliss GVS Pharma Restricted, a Mumbai-based formulations firm.

A supplier of customized synthesis and specialty chemical compounds Anupam Rasayan stated in an announcement it was choosing up 43.3-48.2 per cent fairness stake, adopted by an open supply to the general public shareholders of Bliss GVS Pharma Restricted, at a reported ₹1,360-plus crore. The acquisition has been financed by means of ₹300 crore by means of a time period mortgage, it stated.

Bliss GVS Pharma Ltd is engaged in the event, manufacturing, advertising, and export of a variety of dosage kinds together with suppositories, pessaries, tablets, capsules, syrups, injectables, lotions, and ointments.  Established in 1984, it’s listed on the NSE and BSE, and has a presence throughout regulated and semi-regulated worldwide markets, notably in Africa, Asia, and Latin America, it stated. Bliss GVS Pharma has a diversified portfolio of over 150 branded formulations throughout therapeutic areas similar to antimalarial, anti-fungal, anti-bacterial, anti-inflammatory, and girls’s healthcare.

Anand Desai, Managing Director, Anupam Rasayan, stated the acquisition marks a milestone in constructing an built-in world life sciences and specialty pharmaceutical platform. “It will strategically strengthen our presence throughout the pharmaceutical worth chain, spanning KSMs (key beginning supplies) to completed dosage formulations. Bliss GVS Pharma brings well-established capabilities in area of interest dosage kinds, a powerful worldwide footprint, differentiated manufacturers, and experience throughout a number of therapeutic segments.”

Revealed on Could 23, 2026